MWNA
NERV icon

Marshall Wace North America’s Minerva Neurosciences NERV Stock Holding History

Marshall Wace North America’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16,255
Closed -$1.01M – 1485
2019
Q3 		$1.01M Sell
16,255
-486
-3% -$27.5K 0.01% 689
2019
Q2 		$754K Sell
16,741
-374
-2% -$18.7K ﹤0.01% 813
2019
Q1 		$1.08M Sell
17,115
-10,393
-38% -$625K 0.01% 650
2018
Q4 		$1.48M Sell
27,508
-41,951
-60% -$3.07M 0.01% 516
2018
Q3 		$6.97M Buy
69,459
+17,309
+33% +$1.3M 0.05% 262
2018
Q2 		$3.44M Sell
52,150
-9,984
-16% -$606K 0.02% 612
2018
Q1 		$3.11M Buy
62,134
+2,801
+5% +$135K 0.02% 688
2017
Q4 		$2.87M Sell
59,333
-1,255
-2% -$62.2K 0.02% 736
2017
Q3 		$3.88M Sell
60,588
-11,388
-16% -$653K 0.02% 622
2017
Q2 		$5.18M Buy
71,976
+17,955
+33% +$1.16M 0.04% 491
2017
Q1 		$3.46M Buy
+54,021
New +$4.2M 0.03% 474

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Marshall Wace North America's NERV Position: Q4 2019 in Review

Marshall Wace North America sold out of Minerva Neurosciences (NERV) in Q4 2019, closing a stake of 16,255 shares — an estimated $1.01M sold.

Marshall Wace North America first reported a position in NERV in Q1 2017 and held it in 11 quarters. The position peaked at $6.97M in Q3 2018. 92 funds tracked by Wall St. Rank hold NERV as of Q4 2019.

  • Marshall Wace North America reported no remaining Minerva Neurosciences position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace North America sold 16,255 Minerva Neurosciences shares in Q4 2019, an estimated $1.01M.
  • Marshall Wace North America first reported a position in Minerva Neurosciences in Q1 2017 and held it in 11 quarters.
  • Marshall Wace North America's Minerva Neurosciences position peaked at $6.97M in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.